Interpace Biosciences: Falls as Q2 rev misses estimates due to COVID-19

Interpace Biosciences

20/10/2020 17:00

** Shares of diagnostic test maker  IDXG.O  fall 9.3% to
$3.62
    ** Co's Q2 revenue of $5.4 mln misses analyst estimates of
$5.9 mln due to reduced demand for its diagnostic tests during
COVID-19 pandemic  urn:newsml:reuters.com:*:nASA01935 
    ** Co's pharma services business, which provides genetic
testing and other services to drug developers and biotech firms
for clinical trials, also takes a hit 
    ** Net loss widens to $5.5 mln from $5.2 mln a year earlier 
    ** IDXG says Q2 was "the hardest hit" by impact of COVID-19
 urn:newsml:reuters.com:*:nGNX7Jjd1Z
      ** Up to Monday's close, stock down 20.2% YTD

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))